Form 4: Candel Therapeutics Director Aguilar-Cordova Disposes of Shares

Director Estuardo Aguilar-Cordova reports the disposition of Candel Therapeutics shares, while also detailing beneficial ownership through various trusts.

Summary

• On February 10, 2025, Estuardo Aguilar-Cordova, a director of Candel Therapeutics, disposed of 31,335 shares of CADL at a price of $8.61 per share.
• Following the transaction, Aguilar-Cordova directly owns 60,000 shares jointly with their spouse.
• Aguilar-Cordova also indirectly owns 173,512 shares, 131,443 shares through the LKA 2022 Revocable Trust, 2,074,942 shares through the Estuardo Aguilar-Cordova 2020 Irrevocable Trust, and 2,013,100 shares through the Laura K. Aguilar 2020 Irrevocable Trust.
• Laura K. Aguilar, also a director, is listed as holding shares through various trusts.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the director selling shares, which could indicate a lack of confidence. However, the director still holds a significant number of shares, both directly and indirectly, which mitigates the negative impact.

Negatives

• A director disposed of a significant number of shares, which could be interpreted negatively by the market.

Risks

• The disposition of shares by a director could signal a lack of confidence in the company's future prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency regarding the transactions of company insiders. These filings are closely monitored by investors to gain insights into management's perspective on the company's stock.

Stakeholder Impact

• Shareholders may react to the news of a director selling shares, potentially impacting the stock price.

Key Dates

Keywords

Candel Therapeutics, CADL, Aguilar-Cordova, Director, Share Disposition, Beneficial Ownership, Form 4, Securities